Home Combination Immunotherapy in Oncology: Harnessing the Power of Many

The development of cancer immunotherapy for Immune checkpoint inhibitors (ICI) resistant cancers has been a challenge. Current ICI-based combination therapy strategies have achieved some, albeit limited, success. A deeper understanding of Tumor Immunity in the Micro Environment (TIME) biology in the IO (Immuno-oncology) will unveil next-generation therapeutic strategies. The dynamic functional interplay within TME brings important insights into the design of effective combinatorial strategies against cancer.

With the advent of novel genomics, computational tools, and understanding of the complex pathways, it has become obvious that the future of cancer therapy relies on effective . . .

Access the full-content and exclusive insights by registering to futurebridge.com.

Benefits to Registered User on FutureBridge

Explore Key trends

Stay on top of your industry related trends and oppotunities.

Access to exclusive content

Get insightful information access without any restrictions.

Trending topics

Learn about fundamental challenges confronted by your industry.

Unrestricted webinar access

Gain access to all upcoming webinars and reply on-demand.

Need a thought partner?

Share your focus area or question to engage with our Analysts through the Business Objectives service.

Submit My Business Objective

Our Clients

Our long-standing clients include some of the worlds leading brands and forward-thinking corporations.

New Feature

Login with your mobile number. Update now.